2019•PubMedRequires access

[Clinical efficacy and safety of combined induction therapy with rituximab and ATG in highly sensitized kidney transplant recipients].

J L Fang, Ziman Chen, Yu-wen GUO, J J Ma, Guangdong Pan, G H Li, Long-gen Xu, L Zhang, Xiaofeng Lai, W Yin, Ziqin Yao, L B Chen

Open publisher page 0 citations

Abstract

Immune-induction therapy that combines Rituximab with ATG can significantly inhibit lymphocyte proliferation. It is effective and safe in treating hypersensitive patients. The survival rate of human/kidney of hypersensitive patients in the short and medium term is comparable to those with low immune risk.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Medicine, Rituximab, Panel reactive antibody, Internal medicine, Renal function, Kidney transplantation, Incidence (geometry), Gastroenterology